|

Cineworld (CINE Stock) share price plunges to a record low

Cineworld share price has dropped by over 40% to a new record low today after the cinema chain announced that recent admission levels had come in below expectations, and that it may well have to take action to bolster its balance sheet and restructure its finances.

Management appears to be blaming a limited film slate that is expected to continue until November 2022, potentially impacting the company’s liquidity position in the near term. Unsurprisingly this hasn’t gone down well with investors over concerns that Cineworld may well have to raise extra capital by way of a shares issue, or other refinancing package.

Today’s announcement is more unexpected given the recent update from US based AMC Entertainment who said that the new Dr.Strange film and Top Gun: Maverick had seen ticket sales double, as US punters flocked back to the big screen.

AMC also said that July saw the highest monthly attendance in US theatres since December 2019 as confidence returned. This raises the rather awkward question as to what AMC are doing well that Cineworld clearly aren’t, as both can’t be right?

Either those two films were very popular, or they weren’t, and if AMC saw record July admissions, Cineworld probably needs to ask why it didn’t. That’s the question shareholders need to pose to management.

It was over a year ago that Cineworld management were facing shareholder revolts over a controversial pay and bonus scheme. Today’s announcement is likely to reignite that debate and pose legitimate questions as to the competence of the current management.

Author

Michael Hewson MSTA CFTe

Michael Hewson MSTA CFTe

Independent Analyst

Award winning technical analyst, trader and market commentator. In my many years in the business I’ve been passionate about delivering education to retail traders, as well as other financial professionals. Visit my Substack here.

More from Michael Hewson MSTA CFTe
Share:

Editor's Picks

EUR/USD remains offered below 1.1800, looks at US data

EUR/USD is still trading on the defensive in the latter part of Thursday’s session, while the US Dollar maintains its bid bias as investors now gear up for Friday’s key release of the PCE data, advanced Q4 GDP prints and flash PMIs.
 

GBP/USD bounces off monthly lows near 1.3430

GBP/USD is sliding in tandem with its risk-sensitive peers, drifting back towards the 1.3430 area, its lowest levels in the month. The move reflects a firmer Greenback, supported by another round of solid US data and a somewhat divided FOMC Minutes.

Gold surrenders some gains, back below $5,000

Gold is giving away part of its earlier gains on Thursday, receding to the sub-$5,000 region per troy ounce. The precious metal is finding support from renewed geopolitical tensions in the Middle East and declining US Treasury yields across the curve in a context of further advance in the Greenback.

XRP edges lower as SG-FORGE integrates EUR stablecoin on XRP Ledger

Ripple’s (XRP) outlook remains weak, as headwinds spark declines toward the $1.40 psychological support at the time of writing on Thursday.

Hawkish Fed minutes and a market finding its footing

It was green across the board for US Stock market indexes at the close on Wednesday, with most S&P 500 names ending higher, adding 38 points (0.6%) to 6,881 overall. At the GICS sector level, energy led gains, followed by technology and consumer discretionary, while utilities and real estate posted the largest losses.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments.